Journal
BLOOD
Volume 123, Issue 22, Pages E123-E133Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2014-02-554634
Keywords
-
Categories
Funding
- Myeloproliferative Neoplasm Foundation
- Starr Cancer Consortium
- National Institutes of Health, National Cancer Institute [1R01CA151949-01]
Ask authors/readers for more resources
Genomic studies have identified somatic alterations in the majority of myeloproliferative neoplasms (MPN) patients, including JAK2 mutations in the majority of MPN patients and CALR mutations in JAK2-negative MPN patients. However, the role of JAK-STAT pathway activation in different MPNs, and in patients without JAK2 mutations, has not been definitively delineated. We used expression profiling, single nucleotide polymorphism arrays, and mutational profiling to investigate a well-characterized cohort of MPN patients. MPN patients with homozygous JAK2V617F mutations were characterized by a distinctive transcriptional profile. Notably, a transcriptional signature consistent with activated JAK2 signaling is seen in allMPN patients regardless of clinical phenotype ormutational status. In addition, the activated JAK2 signature was present in patients with somaticCALRmutations. Conversely, weidentified a gene expression signature ofCALRmutations; this signaturewas significantly enriched in JAK2-mutant MPN patients consistent with a shared mechanism of transformation by JAK2 and CALR mutations. We also identified a transcriptional signature of TET2 mutations in MPN patent samples. Our data indicate that MPN patients, regardless of diagnosis or JAK2 mutational status, are characterized by a distinct gene expression signature with upregulation of JAK-STAT target genes, demonstrating the central importance of the JAK-STAT pathway in MPN pathogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available